减肥药的竞赛已然进入白热化阶段。从最初由GLP-1类药物点燃的临床突破,到礼来与诺和诺德在全球市场的强势对垒,这场比赛在短短几年间推动了一个原本冷门领域迈入数百亿美元级别的商业高地。然而,当多个产品在相似的机制路径上快速堆叠,疗效边际递减、副作用显现、患者依从性问题日益突出,行业的关注焦点正在发生转移。如今的减肥药竞争,不再是单纯的GLP-1比拼,而是向“机制组合、结构创新、口服可及性”的新阶段...
Source Link减肥药的竞赛已然进入白热化阶段。从最初由GLP-1类药物点燃的临床突破,到礼来与诺和诺德在全球市场的强势对垒,这场比赛在短短几年间推动了一个原本冷门领域迈入数百亿美元级别的商业高地。然而,当多个产品在相似的机制路径上快速堆叠,疗效边际递减、副作用显现、患者依从性问题日益突出,行业的关注焦点正在发生转移。如今的减肥药竞争,不再是单纯的GLP-1比拼,而是向“机制组合、结构创新、口服可及性”的新阶段...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.